Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-134222 · Präparat HOS-097542
14 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of tenofovir (90 mg/400 mg q.d.) + AUC: ↔ resulting from co-administration of tenofovir Darunavir/Ritonavir Cmax: ↔ disoproxil, ledipasvir/sofosbuvir and (800 mg q.d. /100 mg q.d.) + Cmin: ↔ darunavir/ritonavir may increase adverse Emtricitabine/Tenofovir disoproxil reactions related to tenofovir disoproxil, (200 mg/245 mg q.d.)1 Sofosbuvir: including renal disorders. The safety of AUC: ↓ 27% (↓ tenofovir disoproxil when used with 35 to ↓ 18) ledipasvir/sofosbuvir and a pharmacokinetic Cmax: ↓ 37% (↓ 48 enhancer (e.g. ritonavir or cobicistat) has not to ↓ 25) been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage 9e95c2741ca6344165e150891b0e58860489346b217de4ab953e65d4ced7d26e · Zeichen 14356–15968 im Abschnitt